Completed PHASE2 INTERVENTIONAL 2-arm NCT00799552

Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

A Phase II, Multi-Center, Double-Masked, Randomized, Placebo Controlled, Study on the Safety and Efficacy of RX-10045 on the Signs and Symptoms of Dry Eye in Every Day Environmental Conditions and During Provocation Using the Controlled Adverse Environment (CAE) Model

Sponsor: Resolvyx Pharmaceuticals, Inc

Conditions Dry Eye Syndrome

Interventions Placebo RX-10045

Updated 7 times since 2017 Last updated: Sep 20, 2010 Started: Nov 30, 2008 Primary completion: May 31, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Dry Eye Syndrome, this trial is completed. The trial is conducted by Resolvyx Pharmaceuticals, Inc and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Resolvyx Pharmaceuticals, Inc

Data source: Resolvyx Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Andover, United States